Novartis'(NYSE: NVS) Zolgensma, after it delivered remarkable results in infants with spinal muscular atrophy (SMA), a deadly genetic disorder. The potential to prevent death in infants by restoring the expression of a critical missing protein is a tremendous advance, but most of the media attention so far has focused on Zolgensma's $2.1 million price tag. Is this price as crazy as it sounds?
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,